SyntheticMR introduces REMyDI™, automatic measurement of myelin volume, at RSNA

STOCKHOLM--()--SyntheticMR AB introduces REMyDI*, automatic quantification of myelin volume in the brain. Easy quantification of myelin allows clinicians to follow myelination in the developing brain and monitor myelin degeneration in patients with demyelinating and neurodegenerative disorders. REMyDI is a unique feature of the SyMRI® post-processing software from SyntheticMR.

Measuring myelin volume with conventional MRI is challenging. With the REMyDI feature in SyMRI, clinicians can now get an automatic volume measurement of myelin from a single 5-6 minute quantitative MRI scan. The automatic post-processing is completed in less than 10 seconds.

"The advantage of retrieving a myelin estimation from a quantitative MR sequence that can also provide relaxometry-based volumetry and multiple contrasts is that a large amount of information is collected using a single, 6-minute long acquisition. At Karolinska we have used REMyDI in studies of MS-patients and patients with neurodegenerative diseases,” says Tobias Granberg, MD, PhD, Karolinska University Hospital, Sweden."

SyntheticMR introduces REMyDI as a part of SyMRI at the annual RSNA conference in Chicago, November 27 – December 2, 2016. The REMyDI feature is available in the SyMRI Research Edition package and will be available for clinical use in the SyMRI NEURO package in 2017.

SyMRI is compatible with MR scanners from leading vendors and will be demonstrated in the booths of our partners at RSNA. SyMRI is a CE-marked product and is FDA 510(k) pending.

*Rapid Estimation of Myelin for Diagnostic Imaging

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI®, delivering multiple, adjustable contrast images and quantitative data from a single scan. SyMRI is available in three packages. SyMRI IMAGE provides fast MRI workflows, allowing high patient throughput. SyMRI NEURO enables automatic segmentation of brain tissue, providing objective decision support. SyMRI Research Edition includes exportable SyMaps™, parametric T1, T2 and PD maps of the brain, allowing the investigation to be taken even further. SyMRI is CE-marked product. SyMRI is a registered trademark in Europe and in the USA. SyntheticMR is listed on the AktieTorget exchange in Stockholm, Sweden. For additional information, please visit www.syntheticmr.com . This information is information that SyntheticMR AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on November 28 2016.

This information was brought to you by Cision http://news.cision.com

Contacts

SyntheticMR AB
Maria Wrethag, Head of Marketing and Investor Relations
+46 76 119 1983
or
Stefan Tell, CEO
+46 73 373 4090.

Contacts

SyntheticMR AB
Maria Wrethag, Head of Marketing and Investor Relations
+46 76 119 1983
or
Stefan Tell, CEO
+46 73 373 4090.